Rigel Pharmaceuticals, Inc. Quarterly report [Sections 13 or 15(d)]

CASH, CASH EQUIVALENTS, RESTRICTED CASH, AND SHORT-TERM INVESTMENTS (Tables)

9 Months Ended

Sep. 30, 2025

Cash, cash equivalents, restricted cash, and short-term investments for the periods presented consist of the following (in thousands):


	As of
	September 30, 2025		December 31, 2024
Cash	$	11,109	$	20,135
Restricted cash		57		—
Money market funds		16,989		16,386
US treasury bills		41,666		7,263
Government-sponsored enterprise securities		18,651		23,177
Corporate bonds and commercial paper		48,728		10,360
	$	137,200	$	77,321
Reported as:
Cash and cash equivalents	$	48,534	$	56,746
Short-term investments		88,609		20,575
Restricted cash reported within other assets		57		—
	$	137,200	$	77,321

Cash equivalents and short-term investments include the following securities with gross unrealized gains and losses (in thousands):


			Gross		Gross
	Amortized		Unrealized		Unrealized
As of September 30, 2025	Cost		Gains		Losses		Fair Value
US treasury bills	$	41,607	$	61	$	(2)	$	41,666
Government-sponsored enterprise securities		18,626		26		(1)		18,651
Corporate bonds and commercial paper		48,716		20		(8)		48,728
Total	$	108,949	$	107	$	(11)	$	109,045


			Gross		Gross
	Amortized		Unrealized		Unrealized
As of December 31, 2024	Cost		Gains		Losses		Fair Value
US treasury bills	$	7,260	$	3	$	—	$	7,263
Government-sponsored enterprise securities		23,174		3		—		23,177
Corporate bonds and commercial paper		10,356		4		—		10,360
Total	$	40,790	$	10	$	—	$	40,800


As of September 30, 2025	Fair Value		Gross Unrealized Losses
US treasury bills	$	5,530	$	(2)
Government-sponsored enterprise securities		4,228		(1)
Corporate bonds and commercial paper		26,655		(8)
Total	$	36,413	$	(11)